October 20, 2016 4:39 PM ET


Company Overview of Presidio Pharmaceuticals, Inc.

Company Overview

Presidio Pharmaceuticals, Inc. discovers and develops small-molecule antiviral therapeutics. The company primarily focuses on the development of therapies for hepatitis C virus (HCV) infection. Its portfolio of products includes pan-genotypic HCV NS5A inhibitors and ravidasvir hydrochloride intended for targeting NS5A and NS5B proteins of HCV. The company was founded in 2006 and is based in San Francisco, California.

1700 Owens Street

Suite 585

San Francisco, CA 94158

United States

Founded in 2006





Key Executives for Presidio Pharmaceuticals, Inc.

Acting President, Chief Financial Officer, Secretary and Director
Co-Founder and Director
Chief Medical Advisor
Age: 68
Vice President of Clinical Research
Special Advisor for Scientific & Corporate Development
Compensation as of Fiscal Year 2016.

Presidio Pharmaceuticals, Inc. Key Developments

Ascletis and Presidio Enter into an Exclusive Licensing Agreement

Ascletis and Presidio announced that they have entered into an exclusive licensing agreement for Presidio's clinical stage, HCV NS5A inhibitor PPI-668, also known as ASC16. The agreement provides Ascletis with exclusive rights to develop and commercialize PPI-668 in Greater China. Presidio will retain all rights in the rest of the world. This licensing agreement for PPI-668 adds a fourth drug candidate in late-stage development to the Ascletis pipeline, which aims to provide innovative therapeutics for important medical needs in China. PPI-668 is a pan-genotypic HCV NS5A inhibitor that has shown high SVR rates in combination with other DAAs in a phase 2 study. Under the terms of the agreement, Ascletis will fund clinical development, manufacturing and commercialization of PPI-668 in greater China and Presidio will receive upfront and development milestone payments, as well as tiered royalties based on product net sales in Greater China.

Pharco Pharmaceuticals Licenses Clinical Stage Hepatitis C Virus (HCV) NS5A Inhibitor PPI-668 from Presidio Pharmaceuticals

Pharco Pharmaceuticals and Presidio Pharmaceuticals announced that they have entered into an exclusive license agreement for Presidio's HCV NS5A inhibitor PPI-668 for development and commercialization to treat HCV infection in Egypt. This exclusive license includes an opportunity for Pharco to expand its licensed territory to one or more additional countries in the MENA region. Pharco will fund clinical development and commercialization of PPI-668 in Egypt, and potentially the MENA region. Presidio will receive upfront and development milestone payments, as well as tiered royalties based on product net sales in Egypt and potentially the MENA region. Pharco made an equity investment in Presidio related to the license agreement.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Presidio Pharmaceuticals, Inc., please visit www.presidiopharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.